Patents by Inventor Llew Keltner
Llew Keltner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230414525Abstract: The present invention provides novel compositions and methods for targeted delivery of therapeutics. In particular, the invention provides compositions comprising a plurality of carriers, such as microbubbles, wherein at least one active agent is associated or co-administered with the plurality of carriers for delivery to a target site, e.g., an organ, a tissue, or a tumor site, in a subject. The present invention also provides methods for treating a disease or condition, methods of targeted delivery of an active agent, e.g., to a target site, in a subject, using the carriers based compositions of the invention. The present invention further provides apparatus, devices and methods for preparing the compositions of the present invention.Type: ApplicationFiled: August 29, 2023Publication date: December 28, 2023Applicant: VESSELON, INC.Inventors: Rhodemann Li, Clayton Larsen, Ernest G. Schutt, Llew Keltner
-
Publication number: 20230058977Abstract: The present invention provides novel compositions and methods for targeted delivery of therapeutics. In particular, the invention provides compositions comprising a plurality of carriers, such as microbubbles, wherein at least one active agent is associated or co-administered with the plurality of carriers for delivery to a target site, e.g., an organ, a tissue, or a tumor site, in a subject. The present invention also provides methods for treating a disease or condition, methods of targeted delivery of an active agent, e.g., to a target site, in a subject, using the carriers based compositions of the invention. The present invention further provides apparatus, devices and methods for preparing the compositions of the present invention.Type: ApplicationFiled: May 12, 2022Publication date: February 23, 2023Applicant: VESSELON, INC.Inventors: Rhodemann Li, Clayton Larsen, Ernest G. Schutt, Llew Keltner
-
Publication number: 20230056481Abstract: The present disclosure is directed to methodologies or technologies for generating a predictor of a disease state (e.g. cancer-therapy efficacy status, cancer therapy progress, cancer prognosis, cancer diagnosis, therapy failure, relapse, recurrence, and the like) based on genomic and proteomic signatures, gene expression, and pathways & networks activation of endogenous human stem cell-associated retroviruses (SCAR). This disclosure is also directed to methods of targeting, designing, and using treatments for clinically intractable malignant tumors.Type: ApplicationFiled: June 28, 2022Publication date: February 23, 2023Applicant: OncoScar LLCInventors: Llew Keltner, Guennadi V. Glinskii
-
Patent number: 10307610Abstract: A prostate treatment system having a light delivery device positionable in a transurethral device for treatment of benign prostatic hyperplasia (BPH). The light delivery device includes light generator, such as light emitting diodes (LED), laser diodes (LDs) or a diffusion quartz fiber tip connected to a light generator or a light emitting polymer which produces light at a selected wavelength or waveband or alternative sources of suitable light energy. The treatment device may further include a temperature monitoring system for monitoring the temperature at the treatment site. A light-activated drug is administered to the treatment site prior to light activation. The light-activated drug therapy induces cell death of the target tissue. The device provides a minimally invasive transurethral method for treatment of BPH or prostate cancer.Type: GrantFiled: January 13, 2017Date of Patent: June 4, 2019Assignee: LIGHT SCIENCES ONCOLOGY INC.Inventors: Llew Keltner, Jay Winship, Erik Hagstrom, Frank Zheng, James C. Chen, Joseph M. Hobbs
-
Publication number: 20180057890Abstract: The present disclosure is directed to methodologies or technologies for generating a predictor of a disease state (e.g. cancer-therapy efficacy status, cancer therapy progress, cancer prognosis, cancer diagnosis, therapy failure, relapse, recurrence, and the like) based on genomic and proteomic signatures, gene expression, and pathways & networks activation of endogenous human stem cell-associated retroviruses (SCAR). This disclosure is also directed to methods of targeting, designing, and using treatments for clinically intractable malignant tumors.Type: ApplicationFiled: May 19, 2017Publication date: March 1, 2018Inventors: Llew Keltner, Guennadi V. Glinskii
-
Publication number: 20170246472Abstract: Systems, devices, and methods are described for providing, among other things, improvement in treatment of abnormal tissues including cancer, utilizing light activated drug therapy. Improvements include the use of optical penetration and drug penetration enhancers, in combination with photosensitizing drugs, and the use of localization aids and implements, which enable treatment of larger tissue volumes using minimal tissue access. The cytotoxic photoactivation process is also improved by using internal guidance to direct the light source to and at the lesion site using a naturally occurring orifice or intravascular access route.Type: ApplicationFiled: September 8, 2015Publication date: August 31, 2017Inventors: James C. CHEN, Llew KELTNER, Alexei N. NAIMUSHIN
-
Publication number: 20170128741Abstract: A prostate treatment system having a light delivery device positionable in a transurethral device for treatment of benign prostatic hyperplasia (BPH). The light delivery device includes light generator, such as light emitting diodes (LED), laser diodes (LDs) or a diffusion quartz fiber tip connected to a light generator or a light emitting polymer which produces light at a selected wavelength or waveband or alternative sources of suitable light energy. The treatment device may further include a temperature monitoring system for monitoring the temperature at the treatment site. A light-activated drug is administered to the treatment site prior to light activation. The light-activated drug therapy induces cell death of the target tissue. The device provides a minimally invasive transurethral method for treatment of BPH or prostate cancer.Type: ApplicationFiled: January 13, 2017Publication date: May 11, 2017Applicant: Purdue Pharmaceutical Products L.P.Inventors: Llew KELTNER, Jay WINSHIP, Erik HAGSTROM, Frank ZHENG, James C. CHEN, Joseph M. HOBBS
-
Publication number: 20160213945Abstract: A photoreactive agent and a drug therapy device including a support member configured to pass through a urethra having proximal and distal ends and a longitudinal internal lumen. A light generator carried by the support member, potted within the lumen, and positioned within the urethra to deliver light to the prostate. The light generator generates a light band with a peak at a preselected wavelength. A power source external to the support member powers the light generator. The positioning element locates the support member within the urethra. A transparent/translucent, integral window is positioned proximate to the prostate and allows light to pass through. The window extends 360 degrees radially from the support member. The light generator has at least LEDs or LOs having a dimension of approximately 0.3 mm×0.3 mm×0.1 mm (length×width×thickness).Type: ApplicationFiled: April 5, 2016Publication date: July 28, 2016Applicant: PURDUE PHARMACEUTICAL PRODUCTS L.P.Inventors: Phillip Burwell, Zihong Guo, Jennifer K. Matson, Steven Ross Daly, David B. Shine, Gary Lichttenegger, Jean Bishop, Nick Yeo, Hugh Narciso, Llew Keltner, Jay Winship, Erik Hagstrom, Frank Zheng, James C. Chen, Joseph M. Hobbs
-
Patent number: 9149651Abstract: An energy treatment system to treat a patient includes an energy delivery device having a plurality of energy emitters used in combination with an energy activatable drug. A mask can be used to define a treatment area. Energy from the energy emitters passes through an optical window of the mask to activate a cosmetically and/or therapeutically effective amount of the activatable drug at the target site to bring about a desired change of tissue, for example, to reduce visibility of one or more blood vessels, while energy from the energy emitters directed outside of the target site is blocked by the mask.Type: GrantFiled: January 8, 2008Date of Patent: October 6, 2015Assignee: PURDUE PHARMACEUTICAL PRODUCTS L.P.Inventors: Llew Keltner, James C. Chen
-
Patent number: 8235975Abstract: A light transmission system to provide photodynamic treatment to a patient includes a single use integrated control module and catheter assembly having a plurality of light emitting diodes (LEDs) to transmit light toward target cells within a patient. The integrated light catheter and control module are used in combination with a light activated drug. Selected operating parameters may be programmed into the control module, or it may be wirelessly programmable in situ prior to use to allow user flexibility to tailor treatment for a particular patient or condition. Among the features that prevent reuse are that the control module lacks access to recharge the power source, and it may include a deactivation module that destroys circuitry or software when triggered. To prevent patient interference when in use, the control module may also be configured to selectively deactivate.Type: GrantFiled: October 14, 2011Date of Patent: August 7, 2012Assignee: Light Sciences Oncology, Inc.Inventors: James C. Chen, Steven R. Daly, Zihong Guo, Llew Keltner, Jeffrey R. Storm
-
Publication number: 20120089207Abstract: A light transmission system to provide photodynamic treatment to a patient includes a single use integrated control module and catheter assembly having a plurality of light emitting diodes (LEDs) to transmit light toward target cells within a patient. The integrated light catheter and control module are used in combination with a light activated drug. Selected operating parameters may be programmed into the control module, or it may be wirelessly programmable in situ prior to use to allow user flexibility to tailor treatment for a particular patient or condition. Among the features that prevent reuse are that the control module lacks access to recharge the power source, and it may include a deactivation module that destroys circuitry or software when triggered. To prevent patient interference when in use, the control module may also be configured to selectively deactivate.Type: ApplicationFiled: October 14, 2011Publication date: April 12, 2012Applicant: Light Sciences Oncology, Inc.Inventors: James C. Chen, Steven R. Daly, Zihong Guo, Llew Keltner, Jeffrey R. Storm
-
Patent number: 8057464Abstract: A light transmission system to provide photodynamic treatment to a patient includes a single use integrated control module and catheter assembly having a plurality of light emitting diodes (LEDs) to transmit light toward target cells within a patient. The integrated light catheter and control module are used in combination with a light activated drug. Selected operating parameters may be programmed into the control module, or it may be wirelessly programmable in situ prior to use to allow user flexibility to tailor treatment for a particular patient or condition. Among the features that prevent reuse are that the control module lacks access to recharge the power source, and it may include a deactivation module that destroys circuitry or software when triggered. To prevent patient interference when in use, the control module may also be configured to selectively deactivate.Type: GrantFiled: May 3, 2006Date of Patent: November 15, 2011Assignee: Light Sciences Oncology, Inc.Inventors: James C. Chen, Steven R. Daly, Zihong Guo, Llew Keltner, Jeffrey R. Storm
-
Publication number: 20100305436Abstract: A method and system is used to locate tissue for removal during a resection. The system includes a container that holds a photoactivatable agent capable of binding with unwanted tissue at a treatment site, a light source, and a viewing device. The light source is adapted to continuously output light that causes fluorescence of the photoactivatable agent in unwanted tissue. The system provides fluorescence-enhanced viewing of the treatment site through the viewing device. The viewing device has a filter that filters out light from the light source that is reflected from the treatment site while allowing a fluorescence emission from the photoactivatable agent to pass therethrough to each eye of the user. The light from the light source and the fluorescence emission are in different regions of the energy spectrum.Type: ApplicationFiled: September 12, 2008Publication date: December 2, 2010Applicant: Light Sciences Oncology , Inc.Inventors: James C. Chen, Llew Keltner
-
Publication number: 20100121252Abstract: An energy treatment system to treat a patient includes an energy delivery device having a plurality of energy emitters used in combination with an energy activatable drug. A mask can be used to define a treatment area. Energy from the energy emitters passes through an optical window of the mask to activate a cosmetically and/or therapeutically effective amount of the activatable drug at the target site to bring about a desired change of tissue, for example, to reduce visibility of one or more blood vessels, while energy from the energy emitters directed outside of the target site is blocked by the mask.Type: ApplicationFiled: January 8, 2008Publication date: May 13, 2010Inventors: Llew Keltner, James C. Chen
-
Publication number: 20090216300Abstract: A prostate treatment system having a light delivery device positionable in a transurethral device for treatment of benign prostatic hyperplasia (BPH). The light delivery device includes light generator, such as light emitting diodes (LED), laser diodes (LDs) or a diffusion quartz fiber tip connected to a light generator or a light emitting polymer which produces light at a selected wavelength or waveband or alternative sources of suitable light energy. The treatment device may further include a temperature monitoring system for monitoring the temperature at the treatment site. A light-activated drug is administered to the treatment site prior to light activation. The light-activated drug therapy induces cell death of the target tissue. The device provides a minimally invasive transurethral method for treatment of BPH or prostate cancer.Type: ApplicationFiled: January 18, 2007Publication date: August 27, 2009Applicant: Light Sciences Oncology, Inc.Inventors: Llew Keltner, Jay Winship, Erik Hagstrom, Frank Zheng, James C. Chen, Joseph M. Hobbs
-
Publication number: 20070260295Abstract: A light transmission system to provide photodynamic treatment to a patient includes a single use integrated control module and catheter assembly having a plurality of light emitting diodes (LEDs) to transmit light toward target cells within a patient. The integrated light catheter and control module are used in combination with a light activated drug. Selected operating parameters may be programmed into the control module, or it may be wirelessly programmable in situ prior to use to allow user flexibility to tailor treatment for a particular patient or condition. Among the features that prevent reuse are that the control module lacks access to recharge the power source, and it may include a deactivation module that destroys circuitry or software when triggered. To prevent patient interference when in use, the control module may also be configured to selectively deactivate.Type: ApplicationFiled: May 3, 2006Publication date: November 8, 2007Applicants: Light Sciences Corporation, Light Sciences Oncology, Inc.Inventors: James Chen, Steven Daly, Zihong Guo, Llew Keltner, Jeffrey Storm
-
Patent number: RE47491Abstract: A light transmission system to provide photodynamic treatment to a patient includes a single use integrated control module and catheter assembly having a plurality of light emitting diodes (LEDs) to transmit light toward target cells within a patient. The integrated light catheter and control module are used in combination with a light activated drug. Selected operating parameters may be programmed into the control module, or it may be wirelessly programmable in situ prior to use to allow user flexibility to tailor treatment for a particular patient or condition. Among the features that prevent reuse are that the control module lacks access to recharge the power source, and it may include a deactivation module that destroys circuitry or software when triggered. To prevent patient interference when in use, the control module may also be configured to selectively deactivate.Type: GrantFiled: April 1, 2016Date of Patent: July 9, 2019Assignee: LIGHT SCIENCES ONCOLOGY, INC.Inventors: James C. Chen, Steven R. Daly, Zihong Guo, Llew Keltner, Jeffrey R. Storm